Medico Remedies Ltd (MEDICO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Medico Remedies Ltd on NSE and BSE, with an AI summary of each filing.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 09 Nov 2026, 5:30 am
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2026 ,inter alia, to consider and approve To consider and approve, Unaudited ....
Intimation · 09 Nov 2026, 5:30 am
Medico Remedies Schedules Board Meeting on 9th Nov'26 for Q2 Financial Results Medico Remedies Ltd. announced that a meeting of its Board of Directors is scheduled for 9th Nov'26. The board will convene primarily to consider, approve, and take on record the company's unaudited financial results for the quarter ended 30th Sep'26, along with the statutory Limited Review Report thereon.
MEDICO REMEDIES LIMITED has informed the Exchange about Board Meeting to be held on 09-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 09 Nov 2026, 5:30 am
Please find enclosed.
Others (Uncategorized) · 30 Sept 2026, 12:09 am
Medico Remedies Clarifies Share Price and Volume Movement Driven Solely by Market Conditions Medico Remedies clarified to exchanges on 29th Sep'26 that recent price and volume movements in its stock are purely market-driven. The company confirmed there is no undisclosed price-sensitive information, pending announcements, or material events under Regulation 30 of SEBI (LODR) Regulations, 2015, that would impact operational or financial performance. Management reaffirmed its ongoing compliance with regulatory disclosure mandates.
The Exchange has sought clarification from Medico Remedies Ltd on September 29, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 29 Sept 2026, 11:15 pm
Please find enclosed Voting Results and Scrutinizer Report for AGM
Annual General Meeting · 23 Sept 2026, 9:36 pm
Please Find Enclosed Proceedings of 32nd AGM
Annual General Meeting · 22 Sept 2026, 10:24 pm
Please find enclosed.
Others (Uncategorized) · 29 Aug 2026, 9:52 pm
Please find enclosed.
Annual General Meeting · 29 Aug 2026, 9:43 pm
Please find enclosed
Others (Uncategorized) · 17 Aug 2026, 10:17 pm
Medico Remedies Clarifies Stock Movement, Cites Market Conditions In a letter to the BSE on 5th Aug'26, Medico Remedies clarified the recent movement in its share price. The company confirmed there is no pending announcement or undisclosed price-sensitive information under SEBI (LODR) Regulations that would affect its operational performance. Management attributed the stock's price and volume volatility purely to market conditions, stating it is entirely market-driven. The company reiterated its commitment to timely disclosure of all material events to the stock exchange as required.
Please find enclosed outcome
Financial Result · 13 Aug 2026, 11:03 pm
Medico Remedies Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 6,940 (+81.4% YoY | +22.2% QoQ) ■ EBITDA: 330 (+16.8% YoY | -53.8% QoQ) ■ EBITDA Margin (%): 4.8 (-263 bps YoY | -783 bps QoQ) ■ PAT: 252 (+38.5% YoY | -57.0% QoQ) ■ EPS (INR): 0.30 (+36.4% YoY | -57.7% QoQ)
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve 1. To consider and approve, ....
Intimation · 13 Aug 2026, 5:30 am
Medico Remedies Schedules Board Meeting for Q1FY27 Results Medico Remedies Ltd. announced its Board of Directors will meet on 13th Aug'26. The key agenda is to consider and approve the unaudited financial results for the first quarter ending 30th Jun'26. The board will also review the accompanying Limited Review Report. This meeting will set the financial performance benchmark for the start of the fiscal year.
Please find enclosed
Others (Uncategorized) · 05 Aug 2026, 9:52 pm
Medico Remedies Secures $1.41M Government Supply Order from Dominican Republic Medico Remedies Ltd has secured a significant international government supply order from PROMESE/CAL, Dominican Republic, valued at USD 1,406,450 (approx. INR 13.38 Crores). The contract, announced on 5th Aug'26, is for the supply of tablets, capsules, and dry syrups. The company will complete the full order within three months. The order is not a related party transaction, and the promoter group holds no interest in the awarding entity.
The Exchange has sought clarification from Medico Remedies Ltd on August 3, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Others (Uncategorized) · 03 Aug 2026, 11:38 pm
Please find enclosed
Others (Uncategorized) · 29 Jun 2026, 11:43 pm
Medico Remedies' Credit Ratings Reaffirmed by CRISIL On 29th Jun'26, CRISIL reaffirmed Medico Remedies' ratings for its enhanced bank facilities of Rs. 42 crore, up from Rs. 19 crore. The Long-Term rating was reaffirmed at 'Crisil BBB-/Stable' for facilities totaling Rs. 37 crore, which includes a Rs. 19 crore term loan and Rs. 18 crore in packing credits. The Short-Term rating for the Rs. 5 crore non-fund-based facility (Letter of Credit) was reaffirmed at 'Crisil A3'. The rating is valid until 31st Mar'27.
Please find enclosed
Others (Uncategorized) · 04 Jun 2026, 12:07 am
Medico Remedies Fined by Exchanges for Non-Compliance Medico Remedies received a notice from NSE and BSE on 20th May'26 for alleged non-compliance with Regulation 6(1) of SEBI's Listing Regulations. The exchanges levied a penalty of Rs. 56,640 each (inclusive of GST). The company paid the requisite fines on 25th May'26. Medico Remedies stated there is no material impact on its financials or operations from this event. The non-compliance period was from 01st Jan'26 to 17th Feb'26. The company cited inadvertent oversight for the delayed disclosure.
Please find enclosed
Financial Result · 21 May 2026, 11:54 pm
Medico Remedies Q4FY26 PAT Jumps 35% YoY to Rs. 585.66 Lakhs Medico Remedies reported a strong Q4FY26, with revenue from operations at Rs. 5,680.77 lakhs, up 37.5% YoY. Profit After Tax (PAT) grew 34.9% YoY to Rs. 585.66 lakhs, while QoQ PAT more than doubled from Rs. 287.23 lakhs. For the full year FY26, revenue increased 36.7% YoY to Rs. 20,637.73 lakhs, and PAT rose 29.9% YoY to Rs. 1,311.52 lakhs. Basic EPS for Q4FY26 stood at Rs. 0.71, up from Rs. 0.52 YoY. The auditor issued an unmodified opinion on the financial statements.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 21 May 2026, 11:44 pm
Medico Remedies Confirms It Does Not Qualify as a "Large Corporate" Medico Remedies Ltd. confirmed on 21st May'26 that it does not meet SEBI's criteria to be classified as a "Large Corporate" as of 31st Mar'26. This exempts the company from mandatory fundraising norms via debt securities. The company reported outstanding borrowings of INR 0.35 crores as of 31st Mar'26 and holds a CRISIL BBB/Stable credit rating for FY26. This status implies no obligation to meet specified debt issuance targets, a key point for assessing its capital structure and financing flexibility.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held ....
Outcome · 21 May 2026, 11:14 pm
Medico Remedies Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 5,681 (+37.5% YoY | -3.2% QoQ) ■ EBITDA: 715 (+7.3% YoY | +65.1% QoQ) ■ EBITDA Margin (%): 12.6 (-355 bps YoY | +521 bps QoQ) ■ PAT: 586 (+34.9% YoY | +103.9% QoQ) ■ EPS (INR): 0.71 (+36.5% YoY | +102.9% QoQ)
Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve 1. Audited Financial Results ....
Intimation · 21 May 2026, 5:30 am
Medico Remedies Board Meeting to Review Q4 & FY26 Results Medico Remedies Ltd. (BSE: 540937, NSE: MEDICO) has scheduled a Board of Directors meeting on 21st May'26. The primary agenda is to consider and approve the audited financial results for the fourth quarter (Q4) and the full financial year, both ending on 31st Mar'26. Any other business will be addressed with the Chair's permission. This meeting is a key event for the upcoming earnings announcement and will be closely watched for the company's annual performance and outlook.
Please find enclosed
Others (Uncategorized) · 16 Apr 2026, 10:48 pm
Medico Remedies' Penalty Waiver Application Rejected by NSE and BSE Medico Remedies disclosed that its waiver applications, filed on 24th Feb'26 against penalties for non-compliance with SEBI's Regulation 6(1), were rejected by both the BSE and NSE. The rejections were received on 5th Mar'26 and 10th Apr'26, respectively. The company had received SoP notices on 20th Feb'26 from both exchanges, imposing a penalty of Rs. 63,720 each. Medico Remedies states it has since paid the fines and asserts no material impact on its financials or operations from this event.
Please find enclosed
Others (Uncategorized) · 24 Feb 2026, 11:23 pm
Medico Remedies Receives Penalty Notice from Exchanges Medico Remedies received notices from BSE and NSE on 20th Feb'26 for a penalty of Rs. 63,720 each, due to alleged non-compliance with SEBI Listing Regulation 6(1). The company has subsequently filed a waiver application with both exchanges on 24th Feb'26. Management has stated there is no material impact on the company's financials or operations from this event.
Please find enclosed
Outcome · 24 Feb 2026, 10:01 pm
Medico Remedies Appoints New Company Secretary and Compliance Officer Medico Remedies Ltd appointed Ms. Vidhi Ankit Shah as Company Secretary and Compliance Officer, effective 18th Feb'26. The decision was approved by the Board of Directors upon the recommendation of the Nomination and Remuneration Committee. Ms. Shah is an associate member of the ICSI with over nine years of secretarial compliance experience with listed and unlisted companies. A subsequent clarification confirmed the board meeting was held on 18th Feb'26 from 3:30 PM to 4:00 PM, with outcomes filed within regulatory timelines.
Please find enclosed
Change in Management · 18 Feb 2026, 9:49 pm
Medico Remedies Appoints New Company Secretary and Compliance Officer Medico Remedies' Board of Directors approved the appointment of Ms. Vidhi Ankit Shah as the new Company Secretary and Compliance Officer, effective 18th Feb'26. This key managerial personnel appointment was made upon the recommendation of the Nomination and Remuneration Committee. Ms. Shah is an associate member of the Institute of Company Secretaries of India and has over nine years of experience in secretarial compliance for both listed and unlisted companies. There are no disclosed relationships between Ms. Shah and other directors.
Please find attached Quarterly Financial Results for the quarter ended 31st December 2025
Financial Result · 12 Feb 2026, 11:22 pm
Medico Remedies Reports Q3FY26 Results with Strong YoY Revenue Growth Medico Remedies reported a 9.6% YoY rise in net profit to ₹2.87 Cr for Q3FY26, ended 31 Dec'25, with revenue from operations up 48.6% YoY to ₹58.68 Cr. QoQ, revenue and net profit grew 11.5% and 11.8% respectively. Total expenses increased 48.4% YoY to ₹55.53 Cr, driven mainly by higher material costs. Profit before tax stood at ₹3.83 Cr, a 9.6% YoY increase. Basic EPS for the quarter was ₹0.35, compared to ₹0.32 in the prior-year period.